Interpretation notes:
- Abbreviation: ESBL denotes "extended-spectrum beta-lactamase"
- Non-susceptibility to colistin: Not tested until 2016/2017; Initially defined as growth in colistin 2 mg/L, subsequently in 1 mg/L from 2018/2019 onwards
| Year (September to August) |
Total |
Resistant phenotype |
No. of isolates |
| Carbapenem |
ESBL+ |
Ampicillin |
Amoxycillin-clavulanate |
Tetracycline |
Cotrimoxazole |
Nalidixic acid |
Ciprofloxacin |
Chloramphenicol |
Gentamicin |
Netilmicin |
Amikacin |
Nitrofurantoin |
Colistin |
| Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
| No. |
NDM |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
| 2010 / 2011 |
96 |
0 |
0 |
52 |
54.2 |
53 |
55.2 |
- |
- |
8 |
8.3 |
- |
- |
48 |
50.0 |
- |
- |
27 |
28.1 |
- |
- |
35 |
36.5 |
- |
- |
20 |
20.8 |
- |
- |
13 |
13.5 |
- |
- |
16 |
16.7 |
- |
- |
3 |
3.1 |
- |
- |
0 |
0.0 |
- |
- |
2 |
2.1 |
- |
- |
- |
- |
- |
- |
| 2011 / 2012 |
98 |
0 |
0 |
47 |
48.0 |
48 |
49.0 |
- |
- |
7 |
7.1 |
- |
- |
43 |
43.9 |
- |
- |
29 |
29.6 |
- |
- |
36 |
36.7 |
- |
- |
14 |
14.3 |
- |
- |
13 |
13.3 |
- |
- |
16 |
16.3 |
- |
- |
1 |
1.0 |
- |
- |
0 |
0.0 |
- |
- |
3 |
3.1 |
- |
- |
- |
- |
- |
- |
| 2012 / 2013 |
110 |
0 |
0 |
64 |
58.2 |
74 |
67.3 |
- |
- |
7 |
6.4 |
- |
- |
62 |
56.4 |
- |
- |
46 |
41.8 |
- |
- |
43 |
39.1 |
- |
- |
18 |
16.4 |
- |
- |
17 |
15.5 |
- |
- |
8 |
7.3 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
1 |
0.9 |
- |
- |
- |
- |
- |
- |
| 2013 / 2014 |
127 |
0 |
0 |
77 |
60.6 |
82 |
64.6 |
- |
- |
14 |
11.0 |
- |
- |
62 |
48.8 |
- |
- |
45 |
35.4 |
- |
- |
54 |
42.5 |
- |
- |
23 |
18.1 |
- |
- |
14 |
11.0 |
- |
- |
13 |
10.2 |
- |
- |
3 |
2.4 |
- |
- |
0 |
0.0 |
- |
- |
13 |
10.2 |
- |
- |
- |
- |
- |
- |
| 2014 / 2015 |
108 |
0 |
0 |
67 |
62.0 |
76 |
70.4 |
- |
- |
25 |
23.1 |
- |
- |
54 |
50.0 |
- |
- |
43 |
39.8 |
- |
- |
54 |
50.0 |
- |
- |
22 |
20.4 |
- |
- |
25 |
23.1 |
- |
- |
8 |
7.4 |
- |
- |
5 |
4.6 |
- |
- |
3 |
2.8 |
- |
- |
7 |
6.5 |
- |
- |
- |
- |
- |
- |
| 2015 / 2016 |
137 |
0 |
0 |
95 |
69.3 |
101 |
73.7 |
- |
- |
28 |
20.4 |
- |
- |
79 |
57.7 |
- |
- |
62 |
45.3 |
- |
- |
80 |
58.4 |
- |
- |
25 |
18.2 |
- |
- |
23 |
16.8 |
- |
- |
17 |
12.4 |
- |
- |
9 |
6.6 |
- |
- |
3 |
2.2 |
- |
- |
8 |
5.8 |
- |
- |
- |
- |
- |
- |
| 2016 / 2017 |
151 |
0 |
0 |
101 |
66.9 |
104 |
68.9 |
- |
- |
30 |
19.9 |
- |
- |
91 |
60.3 |
- |
- |
71 |
47.0 |
- |
- |
85 |
56.3 |
- |
- |
48 |
31.8 |
- |
- |
47 |
31.1 |
- |
- |
34 |
22.5 |
- |
- |
16 |
10.6 |
- |
- |
1 |
0.7 |
- |
- |
8 |
5.3 |
- |
- |
3 |
2.0 |
- |
- |
| 2017 / 2018 |
159 |
0 |
0 |
99 |
62.3 |
113 |
71.1 |
- |
- |
27 |
17.0 |
- |
- |
104 |
65.4 |
- |
- |
69 |
43.4 |
- |
- |
62 |
39.0 |
- |
- |
30 |
18.9 |
- |
- |
63 |
39.6 |
- |
- |
47 |
29.6 |
- |
- |
3 |
1.9 |
- |
- |
0 |
0.0 |
- |
- |
6 |
3.8 |
- |
- |
0 |
0.0 |
- |
- |
| 2018 / 2019 |
135 |
0 |
0 |
74 |
54.8 |
97 |
71.9 |
- |
- |
25 |
18.5 |
- |
- |
77 |
57.0 |
- |
- |
42 |
31.1 |
- |
- |
35 |
25.9 |
- |
- |
13 |
9.6 |
- |
- |
36 |
26.7 |
- |
- |
12 |
8.9 |
- |
- |
1 |
0.7 |
- |
- |
0 |
0.0 |
- |
- |
5 |
3.7 |
- |
- |
1 |
0.7 |
- |
- |
| 2019 / 2020 |
177 |
1 |
1 |
119 |
67.2 |
152 |
85.9 |
- |
- |
32 |
18.1 |
- |
- |
95 |
53.7 |
- |
- |
65 |
36.7 |
- |
- |
65 |
36.7 |
- |
- |
32 |
18.1 |
- |
- |
51 |
28.8 |
- |
- |
28 |
15.8 |
- |
- |
2 |
1.1 |
- |
- |
1 |
0.6 |
- |
- |
8 |
4.5 |
- |
- |
0 |
0.0 |
- |
- |
| 2020 / 2021 |
160 |
0 |
0 |
104 |
65.0 |
131 |
81.9 |
- |
- |
43 |
26.9 |
- |
- |
113 |
70.6 |
- |
- |
78 |
48.8 |
- |
- |
79 |
49.4 |
- |
- |
76 |
47.5 |
- |
- |
89 |
55.6 |
- |
- |
46 |
28.8 |
- |
- |
4 |
2.5 |
- |
- |
0 |
0.0 |
- |
- |
1 |
0.6 |
- |
- |
0 |
0.0 |
- |
- |
| 2021 / 2022 |
157 |
4 |
4 |
125 |
79.6 |
131 |
83.4 |
- |
- |
38 |
24.2 |
- |
- |
96 |
61.1 |
- |
- |
79 |
50.3 |
- |
- |
74 |
47.1 |
- |
- |
110 |
70.1 |
- |
- |
72 |
45.9 |
- |
- |
41 |
26.1 |
- |
- |
4 |
2.5 |
- |
- |
0 |
0.0 |
- |
- |
7 |
4.5 |
- |
- |
0 |
0.0 |
- |
- |
| 2022 / 2023 |
118 |
0 |
0 |
80 |
67.8 |
95 |
80.5 |
- |
- |
38 |
32.2 |
- |
- |
74 |
62.7 |
- |
- |
61 |
51.7 |
- |
- |
69 |
58.5 |
- |
- |
69 |
58.5 |
- |
- |
59 |
50.0 |
- |
- |
40 |
33.9 |
- |
- |
- |
- |
- |
- |
10 |
8.5 |
- |
- |
3 |
2.5 |
- |
- |
1 |
0.8 |
- |
- |
| 2023 / 2024 |
149 |
2 |
2 |
102 |
68.5 |
125 |
83.9 |
- |
- |
57 |
38.3 |
- |
- |
104 |
69.8 |
- |
- |
84 |
56.4 |
- |
- |
94 |
63.1 |
- |
- |
107 |
71.8 |
- |
- |
88 |
59.1 |
- |
- |
47 |
31.5 |
- |
- |
- |
- |
- |
- |
35 |
23.5 |
- |
- |
2 |
1.3 |
- |
- |
0 |
0.0 |
- |
- |
| 2024 / 2025 |
101 |
3 |
3 |
66 |
65.3 |
78 |
77.2 |
75 |
74.3 |
29 |
28.7 |
9 |
8.9 |
53 |
52.5 |
53 |
52.5 |
35 |
34.7 |
34 |
33.7 |
42 |
41.6 |
28 |
27.7 |
45 |
44.6 |
11 |
10.9 |
41 |
40.6 |
38 |
37.6 |
15 |
14.9 |
14 |
13.9 |
- |
- |
- |
- |
21 |
20.8 |
0 |
0.0 |
2 |
2.0 |
1 |
1.0 |
8 |
7.9 |
8 |
7.9 |
| Year (September to August) |
Total |
Resistant phenotype |
No. of isolates |
| Carbapenem |
ESBL+ |
Ampicillin |
Amoxycillin-clavulanate |
Tetracycline |
Cotrimoxazole |
Nalidixic acid |
Ciprofloxacin |
Chloramphenicol |
Gentamicin |
Netilmicin |
Amikacin |
Nitrofurantoin |
Colistin |
| Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
| No. |
NDM |
OXA-48 |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
| 2010 / 2011 |
185 |
0 |
0 |
0 |
108 |
58.4 |
154 |
83.2 |
- |
- |
22 |
11.9 |
- |
- |
162 |
87.6 |
- |
- |
129 |
69.7 |
- |
- |
137 |
74.1 |
- |
- |
60 |
32.4 |
- |
- |
121 |
65.4 |
- |
- |
76 |
41.1 |
- |
- |
38 |
20.5 |
- |
- |
13 |
7.0 |
- |
- |
28 |
15.1 |
- |
- |
- |
- |
- |
- |
| 2011 / 2012 |
205 |
0 |
0 |
0 |
105 |
51.2 |
177 |
86.3 |
- |
- |
45 |
22.0 |
- |
- |
173 |
84.4 |
- |
- |
151 |
73.7 |
- |
- |
150 |
73.2 |
- |
- |
68 |
33.2 |
- |
- |
127 |
62.0 |
- |
- |
72 |
35.1 |
- |
- |
25 |
12.2 |
- |
- |
13 |
6.3 |
- |
- |
32 |
15.6 |
- |
- |
- |
- |
- |
- |
| 2012 / 2013 |
239 |
0 |
0 |
0 |
138 |
57.7 |
204 |
85.4 |
- |
- |
36 |
15.1 |
- |
- |
212 |
88.7 |
- |
- |
179 |
74.9 |
- |
- |
187 |
78.2 |
- |
- |
86 |
36.0 |
- |
- |
166 |
69.5 |
- |
- |
90 |
37.7 |
- |
- |
26 |
10.9 |
- |
- |
10 |
4.2 |
- |
- |
36 |
15.1 |
- |
- |
- |
- |
- |
- |
| 2013 / 2014 |
214 |
0 |
0 |
0 |
114 |
53.3 |
186 |
86.9 |
- |
- |
56 |
26.2 |
- |
- |
192 |
89.7 |
- |
- |
152 |
71.0 |
- |
- |
159 |
74.3 |
- |
- |
77 |
36.0 |
- |
- |
144 |
67.3 |
- |
- |
68 |
31.8 |
- |
- |
21 |
9.8 |
- |
- |
12 |
5.6 |
- |
- |
50 |
23.4 |
- |
- |
- |
- |
- |
- |
| 2014 / 2015 |
224 |
0 |
0 |
0 |
123 |
54.9 |
194 |
86.6 |
- |
- |
77 |
34.4 |
- |
- |
192 |
85.7 |
- |
- |
173 |
77.2 |
- |
- |
176 |
78.6 |
- |
- |
89 |
39.7 |
- |
- |
158 |
70.5 |
- |
- |
75 |
33.5 |
- |
- |
33 |
14.7 |
- |
- |
4 |
1.8 |
- |
- |
57 |
25.4 |
- |
- |
- |
- |
- |
- |
| 2015 / 2016 |
187 |
5 |
5 |
0 |
91 |
48.7 |
156 |
83.4 |
- |
- |
63 |
33.7 |
- |
- |
163 |
87.2 |
- |
- |
131 |
70.1 |
- |
- |
145 |
77.5 |
- |
- |
71 |
38.0 |
- |
- |
138 |
73.8 |
- |
- |
61 |
32.6 |
- |
- |
29 |
15.5 |
- |
- |
5 |
2.7 |
- |
- |
51 |
27.3 |
- |
- |
- |
- |
- |
- |
| 2016 / 2017 |
217 |
1 |
1 |
0 |
119 |
54.8 |
187 |
86.2 |
- |
- |
73 |
33.6 |
- |
- |
196 |
90.3 |
- |
- |
160 |
73.7 |
- |
- |
170 |
78.3 |
- |
- |
73 |
33.6 |
- |
- |
141 |
65.0 |
- |
- |
75 |
34.6 |
- |
- |
40 |
18.4 |
- |
- |
11 |
5.1 |
- |
- |
65 |
30.0 |
- |
- |
24 |
11.1 |
- |
- |
| 2017 / 2018 |
281 |
14 |
14 |
0 |
167 |
59.4 |
254 |
90.4 |
- |
- |
110 |
39.1 |
- |
- |
266 |
94.7 |
- |
- |
205 |
73.0 |
- |
- |
205 |
73.0 |
- |
- |
88 |
31.3 |
- |
- |
218 |
77.6 |
- |
- |
98 |
34.9 |
- |
- |
22 |
7.8 |
- |
- |
9 |
3.2 |
- |
- |
74 |
26.3 |
- |
- |
6 |
2.1 |
- |
- |
| 2018 / 2019 |
241 |
7 |
7 |
0 |
114 |
47.3 |
219 |
90.9 |
- |
- |
103 |
42.7 |
- |
- |
227 |
94.2 |
- |
- |
178 |
73.9 |
- |
- |
159 |
66.0 |
- |
- |
66 |
27.4 |
- |
- |
167 |
69.3 |
- |
- |
72 |
29.9 |
- |
- |
14 |
5.8 |
- |
- |
8 |
3.3 |
- |
- |
20 |
8.3 |
- |
- |
5 |
2.1 |
- |
- |
| 2019 / 2020 |
308 |
23 |
19 |
4 |
148 |
48.1 |
295 |
95.8 |
- |
- |
129 |
41.9 |
- |
- |
293 |
95.1 |
- |
- |
204 |
66.2 |
- |
- |
201 |
65.3 |
- |
- |
92 |
29.9 |
- |
- |
240 |
77.9 |
- |
- |
101 |
32.8 |
- |
- |
23 |
7.5 |
- |
- |
7 |
2.3 |
- |
- |
21 |
6.8 |
- |
- |
5 |
1.6 |
- |
- |
| 2020 / 2021 |
258 |
21# |
15 |
7 |
116 |
45.0 |
237 |
91.9 |
- |
- |
89 |
34.5 |
- |
- |
242 |
93.8 |
- |
- |
172 |
66.7 |
- |
- |
168 |
65.1 |
- |
- |
131 |
50.8 |
- |
- |
194 |
75.2 |
- |
- |
93 |
36.0 |
- |
- |
14 |
5.4 |
- |
- |
5 |
1.9 |
- |
- |
26 |
10.1 |
- |
- |
3 |
1.2 |
- |
- |
| 2021 / 2022 |
287 |
42 |
36 |
6 |
136 |
47.4 |
255 |
88.9 |
- |
- |
130 |
45.3 |
- |
- |
256 |
89.2 |
- |
- |
179 |
62.4 |
- |
- |
169 |
58.9 |
- |
- |
167 |
58.2 |
- |
- |
204 |
71.1 |
- |
- |
96 |
33.4 |
- |
- |
13 |
4.5 |
- |
- |
8 |
2.8 |
- |
- |
20 |
7.0 |
- |
- |
4 |
1.4 |
- |
- |
| 2022 / 2023 |
291 |
57 |
53 |
4 |
141 |
48.5 |
268 |
92.1 |
- |
- |
127 |
43.6 |
- |
- |
256 |
88.0 |
- |
- |
186 |
63.9 |
- |
- |
175 |
60.1 |
- |
- |
165 |
56.7 |
- |
- |
225 |
77.3 |
- |
- |
78 |
26.8 |
- |
- |
- |
- |
- |
- |
12 |
4.1 |
- |
- |
22 |
7.6 |
- |
- |
13 |
4.5 |
- |
- |
| 2023 / 2024 |
290 |
63 |
58 |
5 |
151 |
52.1 |
261 |
90.0 |
- |
- |
141 |
48.6 |
- |
- |
263 |
90.7 |
- |
- |
181 |
62.4 |
- |
- |
183 |
63.1 |
- |
- |
192 |
66.2 |
- |
- |
238 |
82.1 |
- |
- |
85 |
29.3 |
- |
- |
- |
- |
- |
- |
33 |
11.4 |
- |
- |
24 |
8.3 |
- |
- |
8 |
2.8 |
- |
- |
| 2024 / 2025 |
288 |
71# |
65 |
7 |
152 |
52.8 |
270 |
93.8 |
269 |
93.4 |
119 |
41.3 |
69 |
24.0 |
252 |
87.5 |
252 |
87.5 |
187 |
64.9 |
187 |
64.9 |
209 |
72.6 |
153 |
53.1 |
169 |
58.7 |
87 |
30.2 |
236 |
81.9 |
227 |
78.8 |
107 |
37.2 |
104 |
36.1 |
- |
- |
- |
- |
62 |
21.5 |
6 |
2.1 |
24 |
8.3 |
8 |
2.8 |
12 |
4.2 |
12 |
4.2 |
| Year (September to August) |
Total |
Resistant phenotype |
No. of isolates |
| Carbapenem |
ESBL+ |
Ampicillin |
Amoxycillin-clavulanate |
Tetracycline |
Cotrimoxazole |
Nalidixic acid |
Ciprofloxacin |
Chloramphenicol |
Gentamicin |
Netilmicin |
Amikacin |
Nitrofurantoin |
Colistin |
| Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
| No. |
NDM |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
| 2010 / 2011 |
265 |
0 |
0 |
219 |
82.6 |
239 |
90.2 |
- |
- |
38 |
14.3 |
- |
- |
242 |
91.3 |
- |
- |
177 |
66.8 |
- |
- |
252 |
95.1 |
- |
- |
214 |
80.8 |
- |
- |
109 |
41.1 |
- |
- |
73 |
27.5 |
- |
- |
8 |
3.0 |
- |
- |
4 |
1.5 |
- |
- |
39 |
14.7 |
- |
- |
- |
- |
- |
- |
| 2011 / 2012 |
259 |
0 |
0 |
216 |
83.4 |
239 |
92.3 |
- |
- |
64 |
24.7 |
- |
- |
243 |
93.8 |
- |
- |
197 |
76.1 |
- |
- |
255 |
98.5 |
- |
- |
191 |
73.7 |
- |
- |
160 |
61.8 |
- |
- |
112 |
43.2 |
- |
- |
41 |
15.8 |
- |
- |
18 |
6.9 |
- |
- |
55 |
21.2 |
- |
- |
- |
- |
- |
- |
| 2012 / 2013 |
295 |
0 |
0 |
245 |
83.1 |
263 |
89.2 |
- |
- |
60 |
20.3 |
- |
- |
251 |
85.1 |
- |
- |
205 |
69.5 |
- |
- |
265 |
89.8 |
- |
- |
207 |
70.2 |
- |
- |
186 |
63.1 |
- |
- |
137 |
46.4 |
- |
- |
77 |
26.1 |
- |
- |
59 |
20.0 |
- |
- |
42 |
14.2 |
- |
- |
- |
- |
- |
- |
| 2013 / 2014 |
407 |
0 |
0 |
369 |
90.7 |
390 |
95.8 |
- |
- |
95 |
23.3 |
- |
- |
312 |
76.7 |
- |
- |
217 |
53.3 |
- |
- |
346 |
85.0 |
- |
- |
261 |
64.1 |
- |
- |
177 |
43.5 |
- |
- |
175 |
43.0 |
- |
- |
45 |
11.1 |
- |
- |
10 |
2.5 |
- |
- |
91 |
22.4 |
- |
- |
- |
- |
- |
- |
| 2014 / 2015 |
346 |
0 |
0 |
321 |
92.8 |
335 |
96.8 |
- |
- |
126 |
36.4 |
- |
- |
308 |
89.0 |
- |
- |
232 |
67.1 |
- |
- |
311 |
89.9 |
- |
- |
217 |
62.7 |
- |
- |
132 |
38.2 |
- |
- |
202 |
58.4 |
- |
- |
76 |
22.0 |
- |
- |
9 |
2.6 |
- |
- |
96 |
27.7 |
- |
- |
- |
- |
- |
- |
| 2015 / 2016 |
309 |
0 |
0 |
273 |
88.3 |
283 |
91.6 |
- |
- |
89 |
28.8 |
- |
- |
268 |
86.7 |
- |
- |
204 |
66.0 |
- |
- |
276 |
89.3 |
- |
- |
151 |
48.9 |
- |
- |
92 |
29.8 |
- |
- |
182 |
58.9 |
- |
- |
47 |
15.2 |
- |
- |
0 |
0.0 |
- |
- |
72 |
23.3 |
- |
- |
- |
- |
- |
- |
| 2016 / 2017 |
258 |
0 |
0 |
225 |
87.2 |
232 |
89.9 |
- |
- |
73 |
28.3 |
- |
- |
181 |
70.2 |
- |
- |
158 |
61.2 |
- |
- |
202 |
78.3 |
- |
- |
128 |
49.6 |
- |
- |
111 |
43.0 |
- |
- |
127 |
49.2 |
- |
- |
31 |
12.0 |
- |
- |
4 |
1.6 |
- |
- |
99 |
38.4 |
- |
- |
1 |
0.4 |
- |
- |
| 2017 / 2018 |
206 |
0 |
0 |
159 |
77.2 |
173 |
84.0 |
- |
- |
34 |
16.5 |
- |
- |
155 |
75.2 |
- |
- |
86 |
41.7 |
- |
- |
174 |
84.5 |
- |
- |
83 |
40.3 |
- |
- |
98 |
47.6 |
- |
- |
84 |
40.8 |
- |
- |
16 |
7.8 |
- |
- |
8 |
3.9 |
- |
- |
48 |
23.3 |
- |
- |
1 |
0.5 |
- |
- |
| 2018 / 2019 |
303 |
4 |
4 |
236 |
77.9 |
286 |
94.4 |
- |
- |
96 |
31.7 |
- |
- |
243 |
80.2 |
- |
- |
182 |
60.1 |
- |
- |
253 |
83.5 |
- |
- |
196 |
64.7 |
- |
- |
224 |
73.9 |
- |
- |
194 |
64.0 |
- |
- |
87 |
28.7 |
- |
- |
12 |
4.0 |
- |
- |
40 |
13.2 |
- |
- |
1 |
0.3 |
- |
- |
| 2019 / 2020 |
351 |
0 |
0 |
312 |
88.9 |
329 |
93.7 |
- |
- |
91 |
25.9 |
- |
- |
254 |
72.4 |
- |
- |
193 |
55.0 |
- |
- |
239 |
68.1 |
- |
- |
152 |
43.3 |
- |
- |
204 |
58.1 |
- |
- |
139 |
39.6 |
- |
- |
30 |
8.5 |
- |
- |
3 |
0.9 |
- |
- |
90 |
25.6 |
- |
- |
0 |
0.0 |
- |
- |
| 2020 / 2021 |
343 |
4 |
4 |
303 |
88.3 |
328 |
95.6 |
- |
- |
96 |
28.0 |
- |
- |
257 |
74.9 |
- |
- |
236 |
68.8 |
- |
- |
264 |
77.0 |
- |
- |
247 |
72.0 |
- |
- |
235 |
68.5 |
- |
- |
183 |
53.4 |
- |
- |
41 |
12.0 |
- |
- |
1 |
0.3 |
- |
- |
75 |
21.9 |
- |
- |
8 |
2.3 |
- |
- |
| 2021 / 2022 |
293 |
20 |
20 |
244 |
83.3 |
276 |
94.2 |
- |
- |
88 |
30.0 |
- |
- |
216 |
73.7 |
- |
- |
208 |
71.0 |
- |
- |
242 |
82.6 |
- |
- |
234 |
79.9 |
- |
- |
229 |
78.2 |
- |
- |
197 |
67.2 |
- |
- |
52 |
17.7 |
- |
- |
8 |
2.7 |
- |
- |
51 |
17.4 |
- |
- |
5 |
1.7 |
- |
- |
| 2022 / 2023 |
366 |
0 |
0 |
330 |
90.2 |
357 |
97.5 |
- |
- |
85 |
23.2 |
- |
- |
301 |
82.2 |
- |
- |
206 |
56.3 |
- |
- |
309 |
84.4 |
- |
- |
236 |
64.5 |
- |
- |
323 |
88.3 |
- |
- |
288 |
78.7 |
- |
- |
- |
- |
- |
- |
35 |
9.6 |
- |
- |
52 |
14.2 |
- |
- |
15 |
4.1 |
- |
- |
| 2023 / 2024 |
376 |
0 |
0 |
342 |
91.0 |
367 |
97.6 |
- |
- |
183 |
48.7 |
- |
- |
333 |
88.6 |
- |
- |
236 |
62.8 |
- |
- |
344 |
91.5 |
- |
- |
342 |
91.0 |
- |
- |
312 |
83.0 |
- |
- |
330 |
87.8 |
- |
- |
- |
- |
- |
- |
66 |
17.6 |
- |
- |
90 |
23.9 |
- |
- |
7 |
1.9 |
- |
- |
| 2024 / 2025 |
363 |
6 |
6 |
317 |
87.3 |
347 |
95.6 |
345 |
95.0 |
90 |
24.8 |
31 |
8.5 |
290 |
79.9 |
289 |
79.6 |
246 |
67.8 |
242 |
66.7 |
342 |
94.2 |
325 |
89.5 |
321 |
88.4 |
276 |
76.0 |
306 |
84.3 |
293 |
80.7 |
304 |
83.7 |
301 |
82.9 |
- |
- |
- |
- |
83 |
22.9 |
15 |
4.1 |
56 |
15.4 |
26 |
7.2 |
23 |
6.3 |
23 |
6.3 |
| Year (September to August) |
Total |
Resistant phenotype |
No. of isolates |
| Carbapenem |
ESBL+ |
Ampicillin |
Amoxycillin-clavulanate |
Tetracycline |
Cotrimoxazole |
Nalidixic acid |
Ciprofloxacin |
Chloramphenicol |
Gentamicin |
Netilmicin |
Amikacin |
Nitrofurantoin |
Colistin |
| Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
| No. |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
| 2010 / 2011 |
92 |
0 |
30 |
32.6 |
39 |
42.4 |
- |
- |
5 |
5.4 |
- |
- |
23 |
25.0 |
- |
- |
17 |
18.5 |
- |
- |
27 |
29.3 |
- |
- |
14 |
15.2 |
- |
- |
15 |
16.3 |
- |
- |
13 |
14.1 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
4 |
4.3 |
- |
- |
- |
- |
- |
- |
| 2011 / 2012 |
52 |
0 |
16 |
30.8 |
25 |
48.1 |
- |
- |
4 |
7.7 |
- |
- |
13 |
25.0 |
- |
- |
7 |
13.5 |
- |
- |
15 |
28.8 |
- |
- |
0 |
0.0 |
- |
- |
4 |
7.7 |
- |
- |
2 |
3.8 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
- |
- |
- |
- |
| 2012 / 2013 |
50 |
0 |
15 |
30.0 |
21 |
42.0 |
- |
- |
4 |
8.0 |
- |
- |
13 |
26.0 |
- |
- |
10 |
20.0 |
- |
- |
16 |
32.0 |
- |
- |
8 |
16.0 |
- |
- |
12 |
24.0 |
- |
- |
5 |
10.0 |
- |
- |
1 |
2.0 |
- |
- |
1 |
2.0 |
- |
- |
1 |
2.0 |
- |
- |
- |
- |
- |
- |
| 2013 / 2014 |
42 |
0 |
22 |
52.4 |
27 |
64.3 |
- |
- |
7 |
16.7 |
- |
- |
16 |
38.1 |
- |
- |
16 |
38.1 |
- |
- |
16 |
38.1 |
- |
- |
7 |
16.7 |
- |
- |
11 |
26.2 |
- |
- |
7 |
16.7 |
- |
- |
3 |
7.1 |
- |
- |
0 |
0.0 |
- |
- |
5 |
11.9 |
- |
- |
- |
- |
- |
- |
| 2014 / 2015 |
49 |
0 |
9 |
18.4 |
18 |
36.7 |
- |
- |
4 |
8.2 |
- |
- |
10 |
20.4 |
- |
- |
9 |
18.4 |
- |
- |
8 |
16.3 |
- |
- |
4 |
8.2 |
- |
- |
6 |
12.2 |
- |
- |
2 |
4.1 |
- |
- |
1 |
2.0 |
- |
- |
0 |
0.0 |
- |
- |
2 |
4.1 |
- |
- |
- |
- |
- |
- |
| 2015 / 2016 |
54 |
0 |
27 |
50.0 |
30 |
55.6 |
- |
- |
7 |
13.0 |
- |
- |
24 |
44.4 |
- |
- |
22 |
40.7 |
- |
- |
28 |
51.9 |
- |
- |
16 |
29.6 |
- |
- |
16 |
29.6 |
- |
- |
5 |
9.3 |
- |
- |
2 |
3.7 |
- |
- |
0 |
0.0 |
- |
- |
4 |
7.4 |
- |
- |
- |
- |
- |
- |
| 2016 / 2017 |
29 |
0 |
4 |
13.8 |
6 |
20.7 |
- |
- |
3 |
10.3 |
- |
- |
4 |
13.8 |
- |
- |
5 |
17.2 |
- |
- |
5 |
17.2 |
- |
- |
3 |
10.3 |
- |
- |
5 |
17.2 |
- |
- |
4 |
13.8 |
- |
- |
3 |
10.3 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
| 2017 / 2018 |
35 |
0 |
15 |
42.9 |
17 |
48.6 |
- |
- |
9 |
25.7 |
- |
- |
15 |
42.9 |
- |
- |
11 |
31.4 |
- |
- |
13 |
37.1 |
- |
- |
10 |
28.6 |
- |
- |
14 |
40.0 |
- |
- |
7 |
20.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
2 |
5.7 |
- |
- |
1 |
2.9 |
- |
- |
| 2018 / 2019 |
13 |
0 |
6 |
46.2 |
6 |
46.2 |
- |
- |
0 |
0.0 |
- |
- |
6 |
46.2 |
- |
- |
6 |
46.2 |
- |
- |
7 |
53.8 |
- |
- |
2 |
15.4 |
- |
- |
1 |
7.7 |
- |
- |
1 |
7.7 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
1 |
7.7 |
- |
- |
0 |
0.0 |
- |
- |
| 2019 / 2020 |
29 |
0 |
14 |
48.3 |
23 |
79.3 |
- |
- |
9 |
31.0 |
- |
- |
12 |
41.4 |
- |
- |
9 |
31.0 |
- |
- |
10 |
34.5 |
- |
- |
6 |
20.7 |
- |
- |
10 |
34.5 |
- |
- |
2 |
6.9 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
1 |
3.4 |
- |
- |
1 |
3.4 |
- |
- |
| 2020 / 2021 |
26 |
0 |
17 |
65.4 |
18 |
69.2 |
- |
- |
6 |
23.1 |
- |
- |
16 |
61.5 |
- |
- |
11 |
42.3 |
- |
- |
16 |
61.5 |
- |
- |
13 |
50.0 |
- |
- |
14 |
53.8 |
- |
- |
2 |
7.7 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
1 |
3.8 |
- |
- |
0 |
0.0 |
- |
- |
| 2021 / 2022 |
66 |
0 |
16 |
24.2 |
28 |
42.4 |
- |
- |
13 |
19.7 |
- |
- |
21 |
31.8 |
- |
- |
9 |
13.6 |
- |
- |
20 |
30.3 |
- |
- |
16 |
24.2 |
- |
- |
14 |
21.2 |
- |
- |
4 |
6.1 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
2 |
3.0 |
- |
- |
1 |
1.5 |
- |
- |
| 2022 / 2023 |
60 |
1 |
13 |
21.7 |
30 |
50.0 |
- |
- |
15 |
25.0 |
- |
- |
27 |
45.0 |
- |
- |
21 |
35.0 |
- |
- |
18 |
30.0 |
- |
- |
28 |
46.7 |
- |
- |
22 |
36.7 |
- |
- |
6 |
10.0 |
- |
- |
- |
- |
- |
- |
5 |
8.3 |
- |
- |
2 |
3.3 |
- |
- |
0 |
0.0 |
- |
- |
| 2023 / 2024 |
67 |
0 |
9 |
13.4 |
39 |
58.2 |
- |
- |
7 |
10.4 |
- |
- |
13 |
19.4 |
- |
- |
8 |
11.9 |
- |
- |
21 |
31.3 |
- |
- |
11 |
16.4 |
- |
- |
8 |
11.9 |
- |
- |
6 |
9.0 |
- |
- |
- |
- |
- |
- |
22 |
32.8 |
- |
- |
6 |
9.0 |
- |
- |
0 |
0.0 |
- |
- |
| 2024 / 2025 |
106 |
2 |
25 |
23.6 |
54 |
50.9 |
34 |
32.1 |
11 |
10.4 |
4 |
3.8 |
30 |
28.3 |
30 |
28.3 |
24 |
22.6 |
24 |
22.6 |
39 |
36.8 |
26 |
24.5 |
25 |
23.6 |
8 |
7.5 |
21 |
19.8 |
16 |
15.1 |
8 |
7.5 |
4 |
3.8 |
- |
- |
- |
- |
25 |
23.6 |
3 |
2.8 |
7 |
6.6 |
1 |
0.9 |
5 |
4.7 |
5 |
4.7 |
| Year (September to August) |
Total |
Resistant phenotype |
No. of isolates |
| Carbapenem |
ESBL+ |
Ampicillin |
Amoxycillin-clavulanate |
Tetracycline |
Cotrimoxazole |
Nalidixic acid |
Ciprofloxacin |
Chloramphenicol |
Gentamicin |
Netilmicin |
Amikacin |
Nitrofurantoin |
Colistin |
| Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
| No. |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
| 2010 / 2011 |
181 |
0 |
15 |
8.3 |
36 |
19.9 |
- |
- |
5 |
2.8 |
- |
- |
44 |
24.3 |
- |
- |
29 |
16.0 |
- |
- |
38 |
21.0 |
- |
- |
6 |
3.3 |
- |
- |
10 |
5.5 |
- |
- |
9 |
5.0 |
- |
- |
4 |
2.2 |
- |
- |
1 |
0.6 |
- |
- |
0 |
0.0 |
- |
- |
- |
- |
- |
- |
| 2011 / 2012 |
156 |
0 |
20 |
12.8 |
40 |
25.6 |
- |
- |
7 |
4.5 |
- |
- |
29 |
18.6 |
- |
- |
20 |
12.8 |
- |
- |
20 |
12.8 |
- |
- |
10 |
6.4 |
- |
- |
11 |
7.1 |
- |
- |
11 |
7.1 |
- |
- |
1 |
0.6 |
- |
- |
0 |
0.0 |
- |
- |
3 |
1.9 |
- |
- |
- |
- |
- |
- |
| 2012 / 2013 |
140 |
0 |
15 |
10.7 |
32 |
22.9 |
- |
- |
1 |
0.7 |
- |
- |
24 |
17.1 |
- |
- |
11 |
7.9 |
- |
- |
19 |
13.6 |
- |
- |
3 |
2.1 |
- |
- |
10 |
7.1 |
- |
- |
3 |
2.1 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
- |
- |
- |
- |
| 2013 / 2014 |
175 |
0 |
14 |
8.0 |
49 |
28.0 |
- |
- |
11 |
6.3 |
- |
- |
37 |
21.1 |
- |
- |
24 |
13.7 |
- |
- |
26 |
14.9 |
- |
- |
6 |
3.4 |
- |
- |
24 |
13.7 |
- |
- |
8 |
4.6 |
- |
- |
6 |
3.4 |
- |
- |
2 |
1.1 |
- |
- |
5 |
2.9 |
- |
- |
- |
- |
- |
- |
| 2014 / 2015 |
153 |
0 |
11 |
7.2 |
35 |
22.9 |
- |
- |
10 |
6.5 |
- |
- |
32 |
20.9 |
- |
- |
13 |
8.5 |
- |
- |
20 |
13.1 |
- |
- |
6 |
3.9 |
- |
- |
14 |
9.2 |
- |
- |
7 |
4.6 |
- |
- |
5 |
3.3 |
- |
- |
0 |
0.0 |
- |
- |
6 |
3.9 |
- |
- |
- |
- |
- |
- |
| 2015 / 2016 |
163 |
0 |
23 |
14.1 |
50 |
30.7 |
- |
- |
13 |
8.0 |
- |
- |
45 |
27.6 |
- |
- |
19 |
11.7 |
- |
- |
30 |
18.4 |
- |
- |
7 |
4.3 |
- |
- |
13 |
8.0 |
- |
- |
12 |
7.4 |
- |
- |
9 |
5.5 |
- |
- |
0 |
0.0 |
- |
- |
4 |
2.5 |
- |
- |
- |
- |
- |
- |
| 2016 / 2017 |
146 |
0 |
20 |
13.7 |
53 |
36.3 |
- |
- |
14 |
9.6 |
- |
- |
34 |
23.3 |
- |
- |
24 |
16.4 |
- |
- |
37 |
25.3 |
- |
- |
13 |
8.9 |
- |
- |
13 |
8.9 |
- |
- |
21 |
14.4 |
- |
- |
7 |
4.8 |
- |
- |
2 |
1.4 |
- |
- |
8 |
5.5 |
- |
- |
1 |
0.7 |
- |
- |
| 2017 / 2018 |
104 |
0 |
14 |
13.5 |
27 |
26.0 |
- |
- |
10 |
9.6 |
- |
- |
31 |
29.8 |
- |
- |
15 |
14.4 |
- |
- |
27 |
26.0 |
- |
- |
3 |
2.9 |
- |
- |
16 |
15.4 |
- |
- |
9 |
8.7 |
- |
- |
3 |
2.9 |
- |
- |
2 |
1.9 |
- |
- |
1 |
1.0 |
- |
- |
0 |
0.0 |
- |
- |
| 2018 / 2019 |
96 |
0 |
9 |
9.4 |
29 |
30.2 |
- |
- |
7 |
7.3 |
- |
- |
26 |
27.1 |
- |
- |
17 |
17.7 |
- |
- |
22 |
22.9 |
- |
- |
4 |
4.2 |
- |
- |
9 |
9.4 |
- |
- |
2 |
2.1 |
- |
- |
0 |
0.0 |
- |
- |
1 |
1.0 |
- |
- |
3 |
3.1 |
- |
- |
2 |
2.1 |
- |
- |
| 2019 / 2020 |
28 |
0 |
0 |
0.0 |
19 |
67.9 |
- |
- |
1 |
3.6 |
- |
- |
9 |
32.1 |
- |
- |
5 |
17.9 |
- |
- |
4 |
14.3 |
- |
- |
1 |
3.6 |
- |
- |
4 |
14.3 |
- |
- |
2 |
7.1 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
| 2020 / 2021 |
3 |
0 |
0 |
0.0 |
1 |
33.3 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
1 |
33.3 |
- |
- |
1 |
33.3 |
- |
- |
0 |
0.0 |
- |
- |
1 |
33.3 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
| 2021 / 2022 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| 2022 / 2023 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| 2023 / 2024 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| 2024 / 2025 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Year (September to August) |
Total |
Resistant phenotype |
No. of isolates |
| Carbapenem |
ESBL+ |
Ampicillin |
Amoxycillin-clavulanate |
Tetracycline |
Cotrimoxazole |
Nalidixic acid |
Ciprofloxacin |
Chloramphenicol |
Gentamicin |
Netilmicin |
Amikacin |
Nitrofurantoin |
Colistin |
| Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
Intermediate + Resistant (I+R) |
Resistant Only (R)* |
| No. |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
No. |
% |
| 2010 / 2011 |
196 |
0 |
48 |
24.5 |
70 |
35.7 |
- |
- |
11 |
5.6 |
- |
- |
59 |
30.1 |
- |
- |
32 |
16.3 |
- |
- |
48 |
24.5 |
- |
- |
17 |
8.7 |
- |
- |
25 |
12.8 |
- |
- |
26 |
13.3 |
- |
- |
10 |
5.1 |
- |
- |
6 |
3.1 |
- |
- |
6 |
3.1 |
- |
- |
- |
- |
- |
- |
| 2011 / 2012 |
171 |
0 |
38 |
22.2 |
72 |
42.1 |
- |
- |
13 |
7.6 |
- |
- |
64 |
37.4 |
- |
- |
37 |
21.6 |
- |
- |
55 |
32.2 |
- |
- |
34 |
19.9 |
- |
- |
24 |
14.0 |
- |
- |
21 |
12.3 |
- |
- |
2 |
1.2 |
- |
- |
0 |
0.0 |
- |
- |
4 |
2.3 |
- |
- |
- |
- |
- |
- |
| 2012 / 2013 |
272 |
0 |
57 |
21.0 |
101 |
37.1 |
- |
- |
17 |
6.3 |
- |
- |
97 |
35.7 |
- |
- |
68 |
25.0 |
- |
- |
86 |
31.6 |
- |
- |
30 |
11.0 |
- |
- |
46 |
16.9 |
- |
- |
30 |
11.0 |
- |
- |
7 |
2.6 |
- |
- |
2 |
0.7 |
- |
- |
9 |
3.3 |
- |
- |
- |
- |
- |
- |
| 2013 / 2014 |
196 |
0 |
42 |
21.4 |
83 |
42.3 |
- |
- |
10 |
5.1 |
- |
- |
61 |
31.1 |
- |
- |
36 |
18.4 |
- |
- |
61 |
31.1 |
- |
- |
6 |
3.1 |
- |
- |
22 |
11.2 |
- |
- |
22 |
11.2 |
- |
- |
1 |
0.5 |
- |
- |
0 |
0.0 |
- |
- |
3 |
1.5 |
- |
- |
- |
- |
- |
- |
| 2014 / 2015 |
166 |
0 |
33 |
19.9 |
67 |
40.4 |
- |
- |
15 |
9.0 |
- |
- |
55 |
33.1 |
- |
- |
37 |
22.3 |
- |
- |
43 |
25.9 |
- |
- |
14 |
8.4 |
- |
- |
23 |
13.9 |
- |
- |
26 |
15.7 |
- |
- |
7 |
4.2 |
- |
- |
1 |
0.6 |
- |
- |
6 |
3.6 |
- |
- |
- |
- |
- |
- |
| 2015 / 2016 |
186 |
0 |
52 |
28.0 |
87 |
46.8 |
- |
- |
30 |
16.1 |
- |
- |
62 |
33.3 |
- |
- |
42 |
22.6 |
- |
- |
52 |
28.0 |
- |
- |
24 |
12.9 |
- |
- |
27 |
14.5 |
- |
- |
27 |
14.5 |
- |
- |
15 |
8.1 |
- |
- |
4 |
2.2 |
- |
- |
7 |
3.8 |
- |
- |
- |
- |
- |
- |
| 2016 / 2017 |
201 |
0 |
63 |
31.3 |
96 |
47.8 |
- |
- |
46 |
22.9 |
- |
- |
66 |
32.8 |
- |
- |
55 |
27.4 |
- |
- |
77 |
38.3 |
- |
- |
18 |
9.0 |
- |
- |
40 |
19.9 |
- |
- |
36 |
17.9 |
- |
- |
13 |
6.5 |
- |
- |
3 |
1.5 |
- |
- |
6 |
3.0 |
- |
- |
7 |
3.5 |
- |
- |
| 2017 / 2018 |
184 |
0 |
34 |
18.5 |
59 |
32.1 |
- |
- |
26 |
14.1 |
- |
- |
60 |
32.6 |
- |
- |
30 |
16.3 |
- |
- |
48 |
26.1 |
- |
- |
16 |
8.7 |
- |
- |
23 |
12.5 |
- |
- |
17 |
9.2 |
- |
- |
2 |
1.1 |
- |
- |
1 |
0.5 |
- |
- |
2 |
1.1 |
- |
- |
2 |
1.1 |
- |
- |
| 2018 / 2019 |
136 |
0 |
28 |
20.6 |
56 |
41.2 |
- |
- |
24 |
17.6 |
- |
- |
47 |
34.6 |
- |
- |
35 |
25.7 |
- |
- |
34 |
25.0 |
- |
- |
8 |
5.9 |
- |
- |
19 |
14.0 |
- |
- |
9 |
6.6 |
- |
- |
1 |
0.7 |
- |
- |
0 |
0.0 |
- |
- |
6 |
4.4 |
- |
- |
2 |
1.5 |
- |
- |
| 2019 / 2020 |
64 |
0 |
26 |
40.6 |
48 |
75.0 |
- |
- |
14 |
21.9 |
- |
- |
31 |
48.4 |
- |
- |
23 |
35.9 |
- |
- |
22 |
34.4 |
- |
- |
17 |
26.6 |
- |
- |
22 |
34.4 |
- |
- |
10 |
15.6 |
- |
- |
4 |
6.3 |
- |
- |
0 |
0.0 |
- |
- |
3 |
4.7 |
- |
- |
0 |
0.0 |
- |
- |
| 2020 / 2021 |
9 |
0 |
0 |
0.0 |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
0 |
0.0 |
- |
- |
| 2021 / 2022 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| 2022 / 2023 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| 2023 / 2024 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| 2024 / 2025 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |